0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Resistance to Targeted Therapies in Lymphomas (Paperback, 1st ed. 2019) Loot Price: R2,770
Discovery Miles 27 700
Resistance to Targeted Therapies in Lymphomas (Paperback, 1st ed. 2019): Ana C. Xavier, Mitchell S. Cairo

Resistance to Targeted Therapies in Lymphomas (Paperback, 1st ed. 2019)

Ana C. Xavier, Mitchell S. Cairo

Series: Resistance to Targeted Anti-Cancer Therapeutics, 21

 (sign in to rate)
Loot Price R2,770 Discovery Miles 27 700 | Repayment Terms: R260 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Series: Resistance to Targeted Anti-Cancer Therapeutics, 21
Release date: September 2020
First published: 2019
Editors: Ana C. Xavier • Mitchell S. Cairo
Dimensions: 235 x 155mm (L x W)
Format: Paperback
Pages: 210
Edition: 1st ed. 2019
ISBN-13: 978-3-03-024426-2
Categories: Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
LSN: 3-03-024426-1
Barcode: 9783030244262

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners